Henry Ford Health System Signs Development and Commercialization Agreement with G3 Pharma for its Galectin-3 inhibitors

Shots:

• Henry to get an exclusive option to license US patent application 14/654,140 for Galectin-3 inhibitors and will acquire minority equity in G3 Pharmaceuticals
• The focus of the agreement is to advance therapies for heart failure with preserved ejection fraction (HFpEF) without no approved treatments
• Galectin-3 is a protein for oral use and is indicated for the treatment of diastolic heart failure also known as HFpEF

 Click here to read full press release/ article | Ref: PRNewsWire | Image: LinkedIn